These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 19886836

  • 1. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH, Ellis GM, Chintu N, Cantrell RA, Sinkala M, Aldrovandi GM, Warrier R, Mbewe F, Nakamura K, Stringer EM, Frenkel LM, Stringer JS.
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
    [Abstract] [Full Text] [Related]

  • 2. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Samuel R, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.
    J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
    [Abstract] [Full Text] [Related]

  • 3. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
    Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F, Sinkala M, Smith PJ, Stringer EM, Stringer JS.
    J Acquir Immune Defic Syndr; 2008 Jun 01; 48(2):220-3. PubMed ID: 18520682
    [Abstract] [Full Text] [Related]

  • 4. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, Aldrovandi GM, Stringer EM, Kankasa C, Safrit JT, Stringer JS.
    Lancet; 2007 Nov 17; 370(9600):1698-705. PubMed ID: 17997151
    [Abstract] [Full Text] [Related]

  • 5. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.
    AIDS; 2009 Apr 27; 23(7):825-33. PubMed ID: 19307941
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E, Cotter A, Purswani M, PACTG 394 Study Team.
    Antimicrob Agents Chemother; 2011 Dec 27; 55(12):5914-22. PubMed ID: 21896911
    [Abstract] [Full Text] [Related]

  • 7. HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
    Samuel R, Julian MN, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M.
    J Acquir Immune Defic Syndr; 2016 Dec 01; 73(4):384-389. PubMed ID: 27327263
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ, Study 934 Team.
    J Acquir Immune Defic Syndr; 2009 Oct 01; 52(2):209-21. PubMed ID: 19644384
    [Abstract] [Full Text] [Related]

  • 10. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF, AI266073 Study Group.
    AIDS Patient Care STDS; 2010 Feb 01; 24(2):87-96. PubMed ID: 20156091
    [Abstract] [Full Text] [Related]

  • 11. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.
    J Acquir Immune Defic Syndr; 2006 Dec 15; 43(5):535-40. PubMed ID: 17057609
    [Abstract] [Full Text] [Related]

  • 12. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
    Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL.
    HIV Clin Trials; 2014 Dec 15; 15(5):218-30. PubMed ID: 25350960
    [Abstract] [Full Text] [Related]

  • 13. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.
    HIV Med; 2013 Oct 15; 14(9):571-7. PubMed ID: 23668660
    [Abstract] [Full Text] [Related]

  • 14. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    Clumeck N, Mwamba C, Kabeya K, Matanda S, Vaira D, Necsoi C, Kadiebwe D, Delforge M, Kasamba E, Milolo C, Ilunga J, Kapend L.
    AIDS; 2014 May 15; 28(8):1143-53. PubMed ID: 25028911
    [Abstract] [Full Text] [Related]

  • 15. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
    Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM, iPrEx Study Team.
    J Infect Dis; 2014 Oct 15; 210(8):1217-27. PubMed ID: 24740633
    [Abstract] [Full Text] [Related]

  • 16. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
    Weberschock T, Gholam P, Hueter E, Flux K, SWS Study Centers, Hartmann M.
    Eur J Med Res; 2009 Oct 15; 14(12):516-9. PubMed ID: 20149984
    [Abstract] [Full Text] [Related]

  • 17. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
    Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF.
    J Acquir Immune Defic Syndr; 2010 Nov 15; 55(3):336-44. PubMed ID: 20739898
    [Abstract] [Full Text] [Related]

  • 18. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.
    HIV Clin Trials; 2013 Nov 15; 14(3):81-91. PubMed ID: 23835510
    [Abstract] [Full Text] [Related]

  • 19. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Oct 06; (10):CD008740. PubMed ID: 20927777
    [Abstract] [Full Text] [Related]

  • 20. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, Toole JJ, Cheng AK.
    J Acquir Immune Defic Syndr; 2008 Jan 01; 47(1):74-8. PubMed ID: 17971715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.